Yüklüyor......
THER-26. PHARMACOKINETIC AND UPDATED OUTCOME DATA FROM PNOC-002: A SAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAFV600E, IN CHILDREN WITH RECURRENT/REFRACTORY BRAFV600E MUTANT BRAIN TUMORS
BACKGROUND: Vemurafenib is an orally administered inhibitor of BRAF-V600E kinase approved for the treatment of BRAF-V600E mutated melanoma. We have previously presented favorable radiographic response and safety data for vemurafenib in children with BRAF-V600E mutated brain tumors and report here an...
Kaydedildi:
| Yayımlandı: | Neuro Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6477532/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.231 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|